We just published the study on HMGA2 AML prognostic test

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia is now published in Blood cancer journal.

 

$12.8 million for Leucegene Research

Guy Sauvageau, Josée Hébert and the Leucegene team are awarded $12.8 million in funding from Genome Canada and Genome Quebec to continue their work on AML. Click here for more information.